{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:31:35Z","timestamp":1794267095102,"version":"4.9.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Defense Health Program","award":["HU00012020067"],"award-info":[{"award-number":["HU00012020067"]}]},{"name":"Defense Health Program","award":["HU00012020067"],"award-info":[{"award-number":["HU00012020067"]}]},{"DOI":"10.13039\/100009898","name":"Defense Health Agency","doi-asserted-by":"publisher","award":["HU00011920111"],"award-info":[{"award-number":["HU00011920111"]}],"id":[{"id":"10.13039\/100009898","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009898","name":"Defense Health Agency","doi-asserted-by":"publisher","award":["HU00011920111"],"award-info":[{"award-number":["HU00011920111"]}],"id":[{"id":"10.13039\/100009898","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Immunization Healthcare Branch","award":["HU00012120104"],"award-info":[{"award-number":["HU00012120104"]}]},{"name":"Immunization Healthcare Branch","award":["HU00012120104"],"award-info":[{"award-number":["HU00012120104"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Viruses"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Starting in 2020, we quantified anti-wildtype SARS-CoV-2 spike sera IgG at monthly intervals from generally healthy adults after various doses of mRNA-based COVID-19 vaccination and in the context of hybrid immunity. Confirmed post-vaccination infections and subclinical infections identified by longitudinal serology were removed from vaccine-only analyses. Over 400 days, the two-dose vaccine-alone antibody response decayed at a half-life (\n                    <jats:italic>t<\/jats:italic>\n                    <jats:sub>1\/2<\/jats:sub>\n                    ) of 59.8 days compared with a\n                    <jats:italic>t<\/jats:italic>\n                    <jats:sub>1\/2<\/jats:sub>\n                    of 99.7 days after receipt of one booster dose. In the hybrid immunity model, the\n                    <jats:italic>t<\/jats:italic>\n                    <jats:sub>1\/2<\/jats:sub>\n                    was greater at 241 days. Using cut-offs for correlation of protection obtained in a prior study, we modeled that individuals with hybrid immunity maintain antibody levels above a 75% correlate of immunity for 283 days after an immune-boosting event. These data offer insights into SARS-CoV-2 antibody decay kinetics that may inform COVID-19 vaccine timing in the younger (age under 60), healthy adult population.\n                  <\/jats:p>","DOI":"10.1038\/s44298-025-00156-3","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:23:44Z","timestamp":1761722624000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Estimating the decay of protective antibodies induced by SARS-CoV-2 mRNA vaccination and hybrid immunity"],"prefix":"10.1038","volume":"3","author":[{"given":"McKenna D.","family":"Roe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si\u2019Ana A.","family":"Coggins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily S.","family":"Darcey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Goguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Haines-Hull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara H.","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon D.","family":"Pollett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Mitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Laing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"156_CR1","doi-asserted-by":"publisher","unstructured":"Chow, N. K. N. et al. The effect of pre-COVID and post-COVID vaccination on long COVID: a systematic review and meta-analysis. J. Infect. 89, https:\/\/doi.org\/10.1016\/j.jinf.2024.106358 (2024).","DOI":"10.1016\/j.jinf.2024.106358"},{"key":"156_CR2","doi-asserted-by":"publisher","first-page":"e069761","DOI":"10.1136\/bmj-2021-069761","volume":"376","author":"AS Lauring","year":"2022","unstructured":"Lauring, A. S. et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. Bmj 376, e069761 (2022).","journal-title":"Bmj"},{"key":"156_CR3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S2213-2600(23)00015-2","volume":"11","author":"N Wu","year":"2023","unstructured":"Wu, N. et al. Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. Lancet Respir. Med. 11, 439\u2013452 (2023).","journal-title":"Lancet Respir. Med."},{"key":"156_CR4","doi-asserted-by":"publisher","first-page":"e460","DOI":"10.1093\/cid\/ciac381","volume":"76","author":"MW Tenforde","year":"2023","unstructured":"Tenforde, M. W. et al. Protection of messenger RNA vaccines against hospitalized coronavirus disease 2019 in adults over the first year following authorization in the United States. Clin. Infect. Dis. 76, e460\u2013e468 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"156_CR5","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1001\/jama.2022.0470","volume":"327","author":"EK Accorsi","year":"2022","unstructured":"Accorsi, E. K. et al. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 omicron and delta variants. Jama 327, 639\u2013651 (2022).","journal-title":"Jama"},{"key":"156_CR6","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1056\/NEJMc2119358","volume":"386","author":"I Nemet","year":"2022","unstructured":"Nemet, I. et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 omicron infection. N Engl. J. Med. 386, 492\u2013494 (2022).","journal-title":"N Engl. J. Med."},{"key":"156_CR7","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41591-021-01676-0","volume":"28","author":"H Gruell","year":"2022","unstructured":"Gruell, H. et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat. Med. 28, 477\u2013480 (2022).","journal-title":"Nat. Med."},{"key":"156_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.medj.2023.02.004","volume":"4","author":"SC Moore","year":"2023","unstructured":"Moore, S. C. et al. Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens. Med. 4, 191\u2013215.e199 (2023).","journal-title":"Med."},{"key":"156_CR9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.immuni.2024.01.017","volume":"57","author":"K Srivastava","year":"2024","unstructured":"Srivastava, K. et al. SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase. Immunity 57, 587\u2013599.e584 (2024).","journal-title":"Immunity"},{"key":"156_CR10","doi-asserted-by":"publisher","unstructured":"Lau, C. S., Phua, S. K., Liang, Y. L., Oh, M. L. H. & Aw, T. C. SARS-CoV-2 spike and neutralizing antibody kinetics 90 days after three doses of BNT162b2 mRNA COVID-19 vaccine in Singapore. Vaccines 10, https:\/\/doi.org\/10.3390\/vaccines10020331 (2022).","DOI":"10.3390\/vaccines10020331"},{"key":"156_CR11","doi-asserted-by":"publisher","first-page":"e2310650","DOI":"10.1001\/jamanetworkopen.2023.10650","volume":"6","author":"F Menegale","year":"2023","unstructured":"Menegale, F. et al. Evaluation of waning of SARS-CoV-2 vaccine-induced immunity: a systematic review and meta-analysis. JAMA Netw. Open 6, e2310650 (2023).","journal-title":"JAMA Netw. Open"},{"key":"156_CR12","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","volume":"399","author":"DR Feikin","year":"2022","unstructured":"Feikin, D. R. et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet 399, 924\u2013944 (2022).","journal-title":"Lancet"},{"key":"156_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm0829","volume":"374","author":"RR Goel","year":"2021","unstructured":"Goel, R. R. et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 374, abm0829 (2021).","journal-title":"Science"},{"key":"156_CR14","doi-asserted-by":"publisher","unstructured":"Arunachalam, P. S. et al. Durability of immune responses to mRNA booster vaccination against COVID-19. J. Clin. Investig. 133, https:\/\/doi.org\/10.1172\/jci167955 (2023).","DOI":"10.1172\/jci167955"},{"key":"156_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-25134-0","volume":"12","author":"CS Korosec","year":"2022","unstructured":"Korosec, C. S. et al. Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex. Sci. Rep. 12, 21232 (2022).","journal-title":"Sci. Rep."},{"key":"156_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1287504","volume":"15","author":"E Goguet","year":"2024","unstructured":"Goguet, E. et al. Immune and behavioral correlates of protection against symptomatic post-vaccination SARS-CoV-2 infection. Front. Immunol. 15, 1287504 (2024).","journal-title":"Front. Immunol."},{"key":"156_CR17","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/s41586-024-08315-x","volume":"637","author":"F Jian","year":"2025","unstructured":"Jian, F. et al. Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1. Nature 637, 921\u2013929 (2025).","journal-title":"Nature"},{"key":"156_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06233-1","volume":"21","author":"BM Jackson-Thompson","year":"2021","unstructured":"Jackson-Thompson, B. M. et al. Prospective assessment of SARS-CoV-2 Seroconversion (PASS) study: an observational cohort study of SARS-CoV-2 infection and vaccination in healthcare workers. BMC Infect. Dis. 21, 544 (2021).","journal-title":"BMC Infect. Dis."},{"key":"156_CR19","doi-asserted-by":"publisher","unstructured":"Laing, E. D. et al. Antigen-based multiplex strategies to discriminate SARS-CoV-2 natural and vaccine induced immunity from seasonal human coronavirus humoral responses. medRxiv https:\/\/doi.org\/10.1101\/2021.02.10.21251518 (2021).","DOI":"10.1101\/2021.02.10.21251518"},{"key":"156_CR20","doi-asserted-by":"publisher","first-page":"828","DOI":"10.3201\/eid2804.212037","volume":"28","author":"ED Laing","year":"2022","unstructured":"Laing, E. D. et al. Durability of antibody response and frequency of SARS-CoV-2 Infection 6 months after COVID-19 vaccination in healthcare workers. Emerg Infect. Dis. 28, 828\u2013832 (2022).","journal-title":"Emerg Infect. Dis."}],"container-title":["npj Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44298-025-00156-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44298-025-00156-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44298-025-00156-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:23:45Z","timestamp":1761722625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44298-025-00156-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["156"],"URL":"https:\/\/doi.org\/10.1038\/s44298-025-00156-3","relation":{},"ISSN":["2948-1767"],"issn-type":[{"value":"2948-1767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.D.P. reports that the USU IDCRP, a U.S. Department of Defense DoD Institution, and the HJF were funded under a Cooperative Research and Development Agreement to conduct an unrelated phase III COVID-19 monoclonal antibody immunoprophylaxis trial sponsored by AstraZeneca. The HJF, in support of the USU IDCRP, was funded by the DoD Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense to augment the conduct of an unrelated phase III vaccine trial sponsored by AstraZeneca. Both trials were part of the USG COVID-19 response. Neither is related to the work presented here. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}